Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: About fibrosis markers - how they can use Mac-2 blood tests
Tig


Admin

Status: Offline
Posts: 8994
Date:
About fibrosis markers - how they can use Mac-2 blood tests
Permalink  
 


That was interesting, thanks, Chuck! I am continuously reminded of all the different proteins we carry around that provide so much diagnostic information. This same protein you referenced has been shown to provide information on post hepatectomy liver failure in HCC patients. It also drops following HCV SVR, so there may be a simpler way to test and monitor treatment efficacy.

All this winning is exciting!! smile



__________________

Tig

63 yo GT1A - 5 Mil - A2/F3 - (1996) Intron A - Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 6+ years!

Hep C FAQ   Lab Ref. Ranges  HCV Resistance

Signature Line Set Up/Abbreviations   Payment Assistance

 



Guru

Status: Offline
Posts: 3249
Date:
Permalink  
 

Just yet another helpful tool in judging fibrosis.

Published in Gastroenterology

Journal Scan / Research · June 09, 2017

Mac-2 Binding Protein Glycosylation Isomer Effective for Identifying Liver Fibrosis in Patients With Hepatitis C

BMC Gastroenterology

TAKE-HOME MESSAGE

   - Patients with chronic hepatitis C and a cohort of healthy controls underwent evaluation of serum M2BPGi levels prior to a FibroScan test of liver fibrosis to evaluate the efficacy of M2BPGi in identifying hepatic fibrosis. In the cohort with hepatitis C, the median serum M2BPGi level increased as the fibrosis score increased, and the M2BPGi level could effectively distinguish hepatitis C patients from controls. M2BPGi was significantly associated with liver stiffness measurement (P < .001). The optimal cutoff values for serum M2BPGi were 0.945 for patients with F2 and 1.355 for patients with F4. M2BPGi was superior to all other invasive markers and had the greatest specificity for diagnosing cirrhosis.

     - The use of serum M2BPGi levels is a simple but reliable diagnostic aid for identifying fibrosis in patients with chronic hepatitis C infection.

BACKGROUND

Mac-2 Binding Protein Glycosylation isomer (M2BPGi) is a novel serological glyco-biomarker for staging liver fibrosis. Here, we aimed to evaluate the efficiency of serum M2BPGi in identifying liver fibrosis stages in Chinese patients with chronic hepatitis C infection.

METHODS

Serum M2BPGi levels were evaluated in 680 patients with chronic hepatitis C and 164 healthy controls who underwent the Fibro Scan® test of liver fibrosis. The diagnostic accuracy of serum M2BPGi values was compared to that of other fibrosis markers, including Fibro Scan®, the aspartate transaminase to platelet ratio index (APRI), the fibrosis index based on four factors (FIB4), and the gamma-glutamyltranspeptidase to platelet ratio (GPR).

RESULTS

Among the chronic hepatitis C patients, the median serum M2BPGi level increased with increasing fibrosis score as follows: 0.88 (<F2), 1.70 (F2/F3), and 5.68 (cirrhosis). M2BPGi concentrations could also distinguish between healthy controls (0.38 ± 0.24) and hepatitis C patients (1.57 ± 2.28). After adjusting for potential confounders, M2BPGi was the most significant factor associated with the liver stiffness measurement (effect size = 0.275, P < 0.001). The optimum cutoff values of serum M2BPGi for patients with F2 and F4 were 0.945 and 1.355, respectively. The area under the curve of serum M2BPGi for prediction of significant fibrosis (F>4) using was comparable to that of APRI (0.892 vs. 0.873), while it was superior to that of other alternative markers, including FIB4 (0.818) and GPR (0.851). Compared with other non-invasive markers, M2BPGi had the greatest specificity for diagnosing cirrhosis and cirrhosis in hepatitis C patients.

CONCLUSIONS

Our results suggest that the level of serum M2BPGi would be a simple and reliable diagnostic tool for identifying liver fibrosis stage in Chinese patients with chronic hepatitis.

 

 

 

 

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 64 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.